What is mazdutide?

Mazdutide is a GLP-1 and glucagon receptor dual agonist that was approved in China in 2025 for obesity and type 2 diabetes, the first drug of its exact class approved anywhere in the world. It is not FDA approved and remains investigational in the US, UK, Australia, and Canada, so buying it outside China means buying an unapproved research chemical.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of glp-1 and metabolic peptides. Semaglutide, tirzepatide, retatrutide, and the rest of the incretin and glucagon receptor family.